Matches in Wikidata for { <http://www.wikidata.org/entity/Q91584957> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q91584957 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q91584957 description "scientific article published on 06 April 2020" @default.
- Q91584957 description "wetenschappelijk artikel" @default.
- Q91584957 description "наукова стаття, опублікована 6 квітня 2020" @default.
- Q91584957 name "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 name "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 type Item @default.
- Q91584957 label "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 label "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 prefLabel "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 prefLabel "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 P1433 Q91584957-E4ADF53B-53E3-4D77-AFBC-5983336BC920 @default.
- Q91584957 P1476 Q91584957-1A8A4728-1F92-40C8-9047-58B61628BF4E @default.
- Q91584957 P2093 Q91584957-06FF397A-6AF1-4C66-971A-024507D45F0A @default.
- Q91584957 P2093 Q91584957-3F73F079-9D78-480F-9EF5-B0495B015390 @default.
- Q91584957 P2093 Q91584957-4C7780B7-1F97-40C9-BF94-0BE89683E27C @default.
- Q91584957 P2093 Q91584957-68779D67-B295-4942-AD61-3FFB1ABE57DB @default.
- Q91584957 P2093 Q91584957-A682EB34-4B4C-44DF-9B50-DA7C3EC2A2A4 @default.
- Q91584957 P2093 Q91584957-FDA8CAB0-5B84-47AD-B211-A84435E59ABD @default.
- Q91584957 P31 Q91584957-1DFEEAF2-BFD5-458B-8476-128807A7C875 @default.
- Q91584957 P356 Q91584957-259574F3-8715-4524-BE38-7A565C3D9080 @default.
- Q91584957 P50 Q91584957-78C33C6B-C392-4963-BF74-8F675F916D7F @default.
- Q91584957 P50 Q91584957-B299B5A8-7C9B-4314-AD82-A1AC44BA65D4 @default.
- Q91584957 P50 Q91584957-FEA9D20A-FE17-46A6-AC57-A08BD2FFB455 @default.
- Q91584957 P577 Q91584957-82E6A82C-189E-43DB-9C54-33F2D88CAEC0 @default.
- Q91584957 P698 Q91584957-0B220693-E4CE-4FC6-ABB1-6A4DE19E773D @default.
- Q91584957 P921 Q91584957-4D5A035B-C15A-4766-8AEB-32E495E10772 @default.
- Q91584957 P356 APT.15706 @default.
- Q91584957 P698 32249966 @default.
- Q91584957 P1433 Q4726656 @default.
- Q91584957 P1476 "The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor" @default.
- Q91584957 P2093 "Aurélien Amiot" @default.
- Q91584957 P2093 "Franck Carbonnel" @default.
- Q91584957 P2093 "Julien Kirchgesner" @default.
- Q91584957 P2093 "Laurent Beaugerie" @default.
- Q91584957 P2093 "Matthieu Allez" @default.
- Q91584957 P2093 "Yoram Bouhnik" @default.
- Q91584957 P31 Q13442814 @default.
- Q91584957 P356 "10.1111/APT.15706" @default.
- Q91584957 P50 Q57775864 @default.
- Q91584957 P50 Q91584950 @default.
- Q91584957 P50 Q91584955 @default.
- Q91584957 P577 "2020-04-06T00:00:00Z" @default.
- Q91584957 P698 "32249966" @default.
- Q91584957 P921 Q1472 @default.